Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRd Induction, HDT-ASCT, KRd Consolidation, and Lenalidomide + Dexamethasone Maintenance in High-Risk Smoldering Multiple Myeloma
2024-516908-42-00Phase 2Authorised
- Sponsor
- PETHEMA
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, lenalidomide, dexamethasone and melphalan in smoldering multiple myeloma (SMM), sponsored by PETHEMA. Primary endpoint: Immunophenotypic complete remission at day +100 after induction and HDT-ASCT. Planned start Oct 2024; status: authorised.
02
Drugs
carfilzomiblenalidomidedexamethasonemelphalan
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2024-516908-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516908-42-00.